Marker Therapeutics Inc
NASDAQ:MRKR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Marker Therapeutics Inc
NASDAQ:MRKR
|
US |
|
Beyond Inc
NYSE:BYON
|
US |
|
FIH Mobile Ltd
HKEX:2038
|
CN |
|
Deliveroo PLC
LSE:ROO
|
UK |
|
J
|
JFB Construction Holdings
NASDAQ:JFB
|
US |
|
Blue Ant Media Corp
TSX:BAMI
|
CA |
|
C
|
China National Building Material Co Ltd
HKEX:3323
|
CN |
|
Coeur Mining, Inc
TSX:CDE
|
US |
|
K
|
KMW Co Ltd
KOSDAQ:032500
|
KR |
|
Fortune Indonesia Tbk PT
IDX:FORU
|
ID |
|
Universal Technologies Holdings Ltd
HKEX:1026
|
HK |
|
Xinjiang Tianshan Cement Co Ltd
SZSE:000877
|
CN |
|
A
|
Antong Holdings Co Ltd
SSE:600179
|
CN |
|
C
|
China Water Industry Group Ltd
HKEX:1129
|
HK |
|
TI Fluid Systems PLC
LSE:TIFS
|
UK |
|
C
|
Compania Sud Americana de Vapores SA
SGO:VAPORES
|
CL |
Marker Therapeutics Inc
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 56 full-time employees. The company went IPO on 2016-11-08. The firm specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The firm has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. The company has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The firm is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 56 full-time employees. The company went IPO on 2016-11-08. The firm specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The firm has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. The company has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The firm is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.
Capital Raise: Marker Therapeutics completed a $56.5 million public offering, significantly strengthening its balance sheet.
Cash Runway: The company ended Q1 with $64.5 million in cash, which is expected to fund operations into Q1 2023.
Clinical Progress: MT-401 began dosing in the safety lead-in portion of its Phase II AML trial, with plans to open the main trial in Q3 2021.
Manufacturing Improvements: Marker reported a 50% reduction in manufacturing time and major process simplifications, which are expected to lower costs and improve scalability.
Strong Early Data: MT-401 continues to show promising safety and efficacy signals in AML, with no major adverse events observed and favorable survival outcomes reported from academic studies.
Focus on Expansion: The company is preparing to open more clinical sites and is considering additional indications, though AML remains the primary focus.
